Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SCHI 871/9-1, SCHI 871/11-1, SCHI 871/8-1, INST 380/124-1, SFB 850, 992,1381 (Project-ID 403222702), SFB850-Project Z1 (INST 39/766-3), PA 2807/3-1, Schu688/15-1, GR 1748/6-1, INST 39/900-1)
Signalling Research Centres BIOSS and CIBSS (CIBSS - EXC-2189 - Project ID 390939984)
German-Israel Foundation (I-1444-201.2/2017)
ERA-PerMed (BMBF) program on personalized medicine (01KU1916A, projects 01KU1915A)
Received: 28 October 2019
Accepted: 10 February 2020
First Online: 17 February 2020
Ethics approval and consent to participate
: Human tissue samples were obtained from patients under institutional review board (IRB)-approved protocols following written informed consent. The institutional review board of the University of Cologne approved the study of these cases. The tumor samples were histologically assessed to have a purity of at least 70%, and the matched normal tissue was confirmed to be free of tumor cells.
: Not applicable.
: The authors declare that they have no competing interests.